Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger
Hansoh Pharmaceutical (HKG: 3692) announced a dual strategic transaction involving its portfolio company Avere Therapeutics,...
Travere Therapeutics
Everest Medicines Secures $1.14 Billion Deal with Travere Therapeutics for Next-Gen BTK Inhibitor Civorebrutinib in Global Kidney Disease Market
Everest Medicines (HKG: 1952) announced a strategic licensing agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX),...